chemistry | pharmaphorum

Skip to main content

Tuesday 8 October 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

chemistry

R&D

5th Commercializing Flow Chemistry Summit banner

Partner Content

The 5th Commercializing Flow Chemistry Summit

The 5th Commercializing Flow Chemistry Summit marks a pivotal year, introducing a significant shift in content to address the evolving needs of the pharmaceutical manufacturing ind

R&D

greener catalysis

A greener catalysis: Talking sustainable, scalable chemistry...

As King’s College London (KCL) scientists are once more in the headlines – this time with new ‘plug and play’ drug delivery technology that could offer a

Partner Content

300x300-Drug-Discovery-Chemistry

Partner Content

Drug Discovery Chemistry - Speaker Interviews with GSK &...

Exclusive Speaker Interviews Released with GSK & Roche

Partner Content

300x300-Drug-Discovery-Chemistry

Partner Content

SMi’s Drug Discovery Chemistry announces key industry speake...

SMi’s Drug Discovery Chemistry brochure available

Editor's Picks

Mounjaro and Zepbound shortages over, declares FDA

Amgen to face investor lawsuit over $10.7bn tax liability disclosure

Gilead strikes deal to expand HIV drug access in 120 countries

Blue Shield of California bypasses PBMs to slash Humira prices by 90%

J&J's 340B rebate scheme stymied by strong-arm HRSA letter

News

AviadoBio chief executive Lisa Deschamps

Astellas places $2bn+ bet on AviadoBio dementia gene therapy

Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Needle with colourful threads

Sponsored

Global reach, personal touch: Mastering customer engagement ...

In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company